Combination therapy for prostate cancer

Abstract

Provided are methods and compositions, for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib; a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.

Description

technical field [0001] The present disclosure relates to the use of small molecule therapeutics for the treatment of prostate cancer. Background technique [0002] Prostate cancer is the most common non-cutaneous malignancy in men and the second leading cause of cancer-related death in men in the Western world. Prostate cancer results from the uncontrolled growth of abnormal cells in the prostate gland. Once a prostate cancer tumor develops, androgens such as testosterone promote the growth of the prostate cancer. In its early stages, localized prostate cancer is usually cured with local therapies including, for example, surgical resection of the prostate and radiation therapy. However, when local therapy fails to cure prostate cancer, which is not curable in as many as one third of men, the disease progresses to incurable metastatic disease (i.e., disease in which the cancer spreads from one part of the body to another ). [0003] For many years, the established standar...

AI Technical Summary

Problems solved by technology

If not repaired, DSBs lead to cell death

When PARP inhibitors are used to treat tumor cells with defects in DNA repair involving the HR pathway (e.g., breast cancer gene [BRCA]-1 / 2), they are unable to efficiently and accurately repair DSBs, which will create a synthetic lethal condition

Images